Executive Management

Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

Ingrid Brands is the Chief Innovation and Strategy Officer of ImmunoPrecise Antibodies, with over two decades in management and senior research roles. She has made significant contributions to the field of medicine and neurorehabilitation. 

Throughout her career, Dr. Brands has pioneered innovative approaches in neuropsychological rehabilitation, enhancing the care provided to patients with acquired brain injuries. She has held respected research positions at esteemed institutions such as Libra Revalidatie & Audiologie and the Department of Rehabilitation at Erasmus University. 

Dr. Brands holds a Ph.D. in neurorehabilitation from the University of Maastricht and graduated with distinction from the University of Leuven, specializing in Physical Medicine and Rehabilitation (PM&R). Her commitment to advancing the field is evident in her academic achievements and active involvement in professional committees. 

Under Dr. Brands' leadership, IPA and its subsidiary BioStrand continue to evolve, utilizing cutting-edge research and technology to drive advancements in genetic research. Her dedication to innovation and patient care serves as the driving force behind IPA's achievements. 

Dirk Van Hyfte is the Chief Technology Officer of ImmunoPrecise Antibodies. With a degree in Medicine and specialization as a Psychiatrist from the prestigious University of Leuven in Belgium, Dirk's expertise extends beyond the realms of technology and business.

As a serial entrepreneur, Dirk has already made significant contributions to the field, with several of his groundbreaking ideas earning him patents. Notably, his remarkable achievement, iKnow, caught the attention of IT provider InterSystems, leading to its acquisition in 2010.

In addition to his entrepreneurial ventures, Dirk serves as a Bio-Medical Advisor, seamlessly blending his medical, AI-analytics, technological, and business acumen. He leverages his profound understanding of medical artificial intelligence, having obtained a PhD in the field from Nijmegen University in the Netherlands.

Dirk’s leadership brings a unique combination of healthcare systems knowledge and AI-driven strategy, positioning IPA at the forefront of industry innovation.

Dr. Ilse Roodink serves as Chief Scientific Officer (CSO) of ImmunoPrecise Antibodies, supporting the company’s global research and development teams. Prior to her appointment as CSO, she held different scientific positions at the Company’s Dutch facility in Oss from 2013 until 2021. In her last role as Scientific Director of ImmunoPrecise Europe, Dr. Roodink was overseeing contract research project execution and management and actively involved in the integration of innovative technologies supporting antibody characterization and engineering. Following its establishment in 2019, Dr. Roodink has served as Chairwoman of Talem Therapeutics’ Scientific Advisory Committee, leading the development of Talem’s pipeline assets.

Dr. Roodink graduated from Radboud University of Nijmegen, the Netherlands with a Master’s degree in Biomedical Health Sciences and a Ph.D. in Medical Sciences. Her work, resulting in several peer-reviewed publications, focused on platform development to facilitate the discovery of antibodies specifically recognizing native tumor targets.

Frédéric Chabot is the Head of Corporate Development at ImmunoPrecise Antibodies (IPA), focusing on M&A, strategic partnerships, and corporate initiatives. He began working with IPA in 2017, contributing in various roles before assuming his current position. With over 26 years of experience in finance and corporate strategy, he navigates biotech investments and market expansion.

Previously, he served as an International Liaison at Contact Financial, an advisory firm specializing in capital raising and investor relations for TSX and TSX-V listed companies. Over nine years, he worked on investor awareness programs and fundraising initiatives, supporting startups and early-stage companies.

Kari Graber serves as the Vice President of Commercial Services for ImmunoPrecise Antibodies, and is responsible for the overall leadership and implementation of the Project Management program throughout ImmunoPrecise’s global family of companies. She has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers, and spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Prior to joining ImmunoPrecise, Ms. Graber served at Aldevron LLC, where she held a client relations management role for their antibody services platform. She holds a Bachelor of Science in Food Science & Technology and a Minor in Microbiology.